Stock Analiz

Solana Co HSDT

Biotechnology: Electromedical & Electrotherapeutic Apparatus · data as of November 13, 2026

$1.73Market cap $109M
Open the interactive analysis →

Solana Co (HSDT) is a healthcare company listed in the US with a market value of about $109M. In the twelve months to September 30, 2026 it had revenue of $15M and net income of $301M, a net margin of 2040.4%.

Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 0.0, 5-year revenue growth of 56% a year, a 5-year average ROIC of -449%.

About Solana Co

Solana Co is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus. Revenue went from $478000 in 2018 to $6M in 2025, growth of about 43.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 6187636% over three years (dilution for shareholders). It spends 58% of revenue on research and development.

Score: 2.2 / 5

Value2/5
Future growth4/5
Track record1/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • ROE above 15%

Valuation

P/E (TTM)0.0
Forward P/E—
P/FCF—
P/S7.4
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-65.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)1057.1%
Revenue growth (5 yrs, per year)55.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1914.7%
ROIC (5-yr avg.)-448.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$15M$6M$520000$644000$787000$522000$661000$1M$478000——
Net income$301M-$41M-$12M-$9M-$14M-$18M-$14M-$10M-$29M-$28M-$7M
Free cash flow-$71M—-$11M-$10M-$14M-$13M-$12M-$21M-$20M-$20M—
EPS (diluted)$87.97$-0.62$-1094.09$-3676.68$-13163.81$-93184.39$-148994.02$-164019.68$-556834.03$-662897.65$-53031.81
Net margin2040.4%-679.6%-2258.1%-1374.2%-1788.1%-3473.6%-2137.7%-653.8%-5988.1%——
ROIC—-81.0%-1298.1%-516.3%-187.8%-161.1%-363.1%-370.8%-199.7%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $3.00, 73% above the current price; targets range from $3.00 to $3.00; the consensus rating is “Strong buy”; expected EPS is $-0.74 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Solana Co’s P/E ratio?

About 0.0, based on the last twelve months of diluted earnings per share.

Does Solana Co pay a dividend?

Not currently.

Is Solana Co a good stock to buy?

We do not give buy or sell advice. Solana Co scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.